Back

Clinical impact of atrial fibrillation on cardiac parameters and long-term outcomes in patients with transthyretin amyloid cardiomyopathy in the era of disease-modifying therapy

28 August 2026 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation: real-world outcomes and risk Heart Failure in Atrial Fibrillation ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Shuichiro Yamauchi

Okayama (Japan)

5 More presentations in this session

Presentation thumbnail
Impact of frailty on in-hospital and long-term outcomes after atrial fibrillation ablation in patients aged ≥75 years
Doctor H. Altamimi (Concord West, AU)
Abstract Slides Video
Presentation thumbnail
Long-term ozone exposure and risk of cerebrovascular and cardiovascular events in patients with atrial fibrillation: a nationwide cohort study
Doctor C. Wang (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
Clinical outcomes following atrial fibrillation diagnosis in routine practice: a nationwide cohort study in Sweden
Professor J. Engdahl (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
On-label versus off-label direct oral anticoagulant dosing patterns and associated outcomes in atrial fibrillation: a real-world cohort analysis
Professor G. Patti (Novara, IT)
Abstract Slides Video
Presentation thumbnail
Prognostic associations of major bleeding in anticoagulated patients with atrial fibrillation after TAVI: a post hoc analysis of the ENVISAGE-TAVI AF trial
Doctor G. Dangas (New York, US)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation: real-world outcomes and risk

The Event

Event poster

ESC Congress 2026

28 August 2026 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Atrial fibrillation is associated with worse outcome in patients with wild-type transthyretin amyloid cardiomyopathy
18 May 2025
thumbnail
Congress Presentation
Long-term improvement in myocardial structure and function in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with acoramidis compared with a natural history cohort
28 August 2026
thumbnail
Congress Presentation
Top cardiovascular science papers impacting arrhythmia practice (EHJ 2025)
13 April 2026
thumbnail
Congress Presentation
Acoramidis treatment is associated with a lower incidence of atrial fibrillation/atrial flutter events in patients with ATTR-CM: post-hoc analyses of the ATTRibute-CM trial
18 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources